3 Stocks Estimated To Be Trading Up To 42.3% Below Intrinsic Value
In This Article:
In the wake of a "red sweep" in the U.S. elections, global markets have experienced a notable rally, with major benchmarks reaching record highs as investors anticipate potential economic growth driven by policy changes. Amid these market dynamics, identifying undervalued stocks becomes increasingly important for investors seeking opportunities that may offer substantial value relative to their intrinsic worth.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Arteche Lantegi Elkartea (BME:ART) | €6.05 | €12.01 | 49.6% |
| Appier Group (TSE:4180) | ¥1670.00 | ¥3374.15 | 50.5% |
| XPEL (NasdaqCM:XPEL) | US$45.67 | US$91.12 | 49.9% |
| Cettire (ASX:CTT) | A$1.585 | A$2.94 | 46.1% |
| Mona YongpyongLtd (KOSE:A070960) | ₩3235.00 | ₩6711.45 | 51.8% |
| AirBoss of America (TSX:BOS) | CA$4.05 | CA$8.27 | 51% |
| KeePer Technical Laboratory (TSE:6036) | ¥3960.00 | ¥7787.76 | 49.2% |
| Redcentric (AIM:RCN) | £1.1625 | £2.32 | 50% |
| Nayuki Holdings (SEHK:2150) | HK$1.59 | HK$3.16 | 49.7% |
| QuinStreet (NasdaqGS:QNST) | US$23.42 | US$46.52 | 49.7% |
Let's dive into some prime choices out of the screener.
BHI
Overview: BHI Co., Ltd. develops, manufactures, and supplies power plant equipment globally with a market cap of ₩400.70 billion.
Operations: Revenue Segments (in millions of ₩):
Estimated Discount To Fair Value: 35.9%
BHI Co., Ltd. is trading at ₩15,040, significantly below its estimated fair value of ₩23,453.66, indicating potential undervaluation based on cash flows. Despite a volatile share price recently and interest payments not well covered by earnings, BHI's revenue growth is forecasted to outpace the KR market at 22.7% annually. Recent inclusion in the S&P Global BMI Index and improved profitability further highlight its strong financial recovery and growth prospects.
-
The analysis detailed in our BHI growth report hints at robust future financial performance.
-
Take a closer look at BHI's balance sheet health here in our report.
Xvivo Perfusion
Overview: Xvivo Perfusion AB (publ) is a medical technology company that develops and markets machines and perfusion solutions for assessing and maintaining organs for transplantation across various regions, with a market cap of SEK14.62 billion.
Operations: The company's revenue segments include Services at SEK81.19 million, Thoracic at SEK501.47 million, and Abdominal at SEK167.94 million.
Estimated Discount To Fair Value: 42.3%
Xvivo Perfusion is trading at SEK464, significantly below its estimated fair value of SEK804.55, highlighting potential undervaluation based on cash flows. The company reported strong financial results with third-quarter sales reaching SEK198.48 million and net income soaring to SEK85.82 million from SEK2.28 million a year ago. Earnings are forecast to grow significantly at 24% annually, outpacing the Swedish market's growth rate and supporting its undervaluation narrative despite low future return on equity expectations.